Immune Thrombocytopenic Purpura – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of primary immune thrombocytopenic purpura (ITP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) and other European countries. We report the prevalence of primary ITP for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s primary ITP forecast will answer the following questions:

  • Of all people diagnosed with primary ITP, how many in each country in the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of primary ITP over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts six primary ITP patient populations, as follows:

  • Diagnosed incident cases of primary ITP.
  • Diagnosed prevalent cases of primary ITP.
  • Newly diagnosed prevalent cases of primary ITP (IWG criteria).
  • Diagnosed prevalent cases of persistent primary ITP (IWG criteria).
  • Diagnosed prevalent cases of chronic primary ITP (IWG criteria).
  • Diagnosed drug-treated cases of primary ITP.

Note: Coverage may vary by country.